Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
28 February 2024 - 11:01PM
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), today announced that Mardi C.
Dier has been appointed Chief Financial Officer.
Ms. Dier has spent more than 20 years in executive
financial leadership roles in the biopharmaceutical industry, with
deep experience in operational and strategic decision making,
capital raising, financial planning and accounting (FP&A),
global supply chain management, investor relations and business
development. She has held Chief Financial Officer positions at
Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and
Acelyrin, Inc.
Bill Sibold, Chief Executive Officer of Madrigal,
stated, “Mardi has an outstanding track record of experience
helping biopharmaceutical companies scale for commercial success,
and her diverse operational and strategic capabilities make her an
ideal addition to the leadership team as Madrigal enters its next
phase of expansion and growth.”
“I am thrilled to be joining the Madrigal team as
the Company ramps up for the launch of resmetirom and continues to
build a more fully integrated organization that will lead the way
in NASH for years to come,” said Ms. Dier. “Madrigal has a unique
opportunity to transform care for patients and become the next
major success story for our industry.”
Ms. Dier was most recently Chief Financial Officer
of Acelyrin, Inc., where she completed the company’s $621 million
initial public offering before departing in August 2023. Prior to
that, Ms. Dier was Chief Financial Officer and Executive Vice
President of Ultragenyx, responsible for leading the corporate
strategy, FP&A, accounting, tax, investor relations, global
corporate communications and information technology functions.
Ultragenyx’s employee base grew 50% during her tenure, expanding
its global commercial presence in the U.S., Latin America, Canada,
Europe and Japan. She joined Ultragenyx from Portola
Pharmaceuticals (acquired by Alexion), where she served as Chief
Financial Officer for 14 years and, most recently, as Chief
Business Officer and Chief Financial Officer. Over the course of
her time at Portola, Ms. Dier oversaw a wide range of functions and
helped scale the organization from one site with fewer than 100
employees to a global organization with multiple sites in the U.S.
and Europe and over 450 employees. Prior to Portola, she served as
Vice President of Investor Relations at Chiron Corporation until
its acquisition by Novartis. Earlier in her career, she worked as
an investment banker at Prudential Securities and, prior to that,
was in the audit department of KPMG Peat Marwick. Ms. Dier serves
on the Board of Directors of ORIC Pharmaceuticals, Prelude
Therapeutics, Synthekine, Inc. and Health Care Royalty and is a
member of the Board of Advisors for the Anderson School of
Management at the University of California, Los Angeles (UCLA). She
holds a B.S. in biology from Stanford University and an M.B.A. from
the Anderson School at UCLA.
Ms. Dier joined Madrigal on February 27, 2024, as
an employee in a Senior Advisor role to the Company’s current Chief
Financial Officer, Alex Howarth, and will move into the Chief
Financial Officer role on March 11, 2024. Mr. Howarth is expected
to continue with the Company as a Senior Advisor until March 31,
2024, to ensure a smooth transition of responsibilities to Ms.
Dier.
“As we welcome Mardi to the Madrigal team, I’d also
like to thank our outgoing Chief Financial Officer Alex Howarth for
his substantial contributions to the Company,” said Bill Sibold.
“Alex served as CFO during a period of rapid growth for Madrigal
and played an instrumental role in establishing the Company’s
strong financial foundation. I wish him well in his future
endeavors.”
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
clinical-stage biopharmaceutical company pursuing novel
therapeutics for nonalcoholic steatohepatitis (NASH), a liver
disease with high unmet medical need. Madrigal’s lead candidate,
resmetirom, is a once-daily, oral, liver-directed THR-β agonist
designed to target key underlying causes of NASH. For more
information, visit www.madrigalpharma.com.
Investor Contact Tina Ventura,
Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates,
Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Apr 2024 to May 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From May 2023 to May 2024